

## Challenge

The study targeting a small and geographically dispersed patient population, made traditional site-based access and participation impractical. Several key obstacles complicated enrollment:

**Limited Site Reach:** Patients were spread across wide regions, and few lived near traditional research sites.

**Strict Eligibility Criteria:** Requirements such as being on a specific medication and maintaining precise blood pressure ranges significantly narrowed the pool of qualified candidates, further limiting the potential for enrollment through brick & mortar sites.

**High Site Activation Burden:** To achieve enrollment goals using a traditional model, the sponsor would have had to activate a large number of sites—driving up costs, timelines, and complexity.

**Participant Burden:** Even those who lived near sites were unwilling to travel for multiple visits in a short time frame due to the inconvenience and time commitment required.

## Solution

Science 37's Direct-to-Patient Site helped the sponsor streamline enrollment and expand access by bringing the trial directly to patients—regardless of their location.

**Single, Direct-to-Patient Site:** Acting as the primary site of record, Science 37 successfully enrolled the majority of study participants across the U.S., eliminating the need for the sponsor to qualify and initiate numerous traditional sites.

**Research-Grade Nursing:** Science 37's nation-wide network of in-house mobile research-grade nurses conducted in-home visits, including repeat assessments just three days apart—dramatically reducing participant burden and travel requirements.

**Streamlined Eligibility Confirmation:** Medical records retrieval and review quickly enabled upfront confirmation of eligibility and minimized screening delays.

## Science 37 Results

Enrolled

**55%**

of Total Study Participants

**98%**

Visit Completion Rate

**Top  
Enrolling  
Site**

Among 45 Sites

Science 37 enrollment: 33  
Avg. brick & mortar enrollment: <1 pt/site



**Scan to Learn More about Our Direct-to-Patient Site.**

© 2025 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

[www.science37.com](http://www.science37.com)



**The First & Only FDA-Inspected  
Direct-to-Patient Site**

Closed Enrollment


5 Months  
Early

contributed 77% of the required completers (n=43) for interim analysis

Performance Summary

	Screened	Enrolled
Science 37	91	33
All brick & mortar Sites	69	27
<b>Total</b>	<b>160</b>	<b>60</b>
Science 37 Contribution	56.0%	55.0%

Site Performance Distribution



Sponsor Collaboration

- Exceptional recruitment and enrollment noted by Sponsor
- Science 37's Site success led to the Sponsor seeking our advice on both recruitment and protocol evaluation
- Science 37 collaboration with the Sponsor led to a protocol amendment that greatly reduced Screen Failure rates
- Science 37 developed helpful hints and best practices the sponsor presented to all study sites, enhancing overall study performance



Scan to Learn More about Our Direct-to-Patient Site.

© 2025 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

[www.science37.com](http://www.science37.com)



The First & Only FDA-Inspected  
Direct-to-Patient Site